Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.

Gray JE, Chiappori A, Williams CC, Tanvetyanon T, Haura EB, Creelan BC, Kim J, Boyle TA, Pinder-Schenck M, Khalil F, Altiok S, Devane R, Noyes D, Mediavilla-Varela M, Smilee R, Hopewell EL, Kelley L, Antonia SJ.

Cancer Immunol Immunother. 2018 Dec;67(12):1853-1862. doi: 10.1007/s00262-018-2236-7. Epub 2018 Sep 12.

2.

Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment.

Holton AB, Sinatra FL, Kreahling J, Conway AJ, Landis DA, Altiok S.

PLoS One. 2017 Jan 13;12(1):e0169797. doi: 10.1371/journal.pone.0169797. eCollection 2017.

3.

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma.

Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, Altiok S, Lynch CC, Sullivan DM, Reed DR.

Sci Rep. 2015 Nov 25;5:16991. doi: 10.1038/srep16991.

4.

Special Technologies for Ex Vivo Analysis of Cancer.

Kreahling JM, Altiok S.

Cancer Control. 2015 Apr;22(2):226-31. Review.

PMID:
26068769
5.

Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma.

Khalil FK, Altiok S.

Cancer Control. 2015 Apr;22(2):193-9. Review.

PMID:
26068764
6.

Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays.

Smith MA, Hall R, Fisher K, Haake SM, Khalil F, Schabath MB, Vuaroqueaux V, Fiebig HH, Altiok S, Chen YA, Haura EB.

Sci Signal. 2015 Jan 13;8(359):ra4. doi: 10.1126/scisignal.2005906.

7.

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.

Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, Haura EB.

J Thorac Oncol. 2014 Jul;9(7):974-82. doi: 10.1097/JTO.0000000000000193.

8.

A woman with swelling of the posterior pharyngeal wall.

Shamekh R, Altiok S, Leon ME.

JAMA Otolaryngol Head Neck Surg. 2014 Jul;140(7):671-2. doi: 10.1001/jamaoto.2014.861. No abstract available.

PMID:
24902797
9.

A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

Gray JE, Haura E, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenck M, Kish JA, Kreahling J, Lush R, Neuger A, Tetteh L, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S.

Clin Cancer Res. 2014 Mar 15;20(6):1644-55. doi: 10.1158/1078-0432.CCR-13-2235. Epub 2014 Jan 15.

10.

Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy.

Foroutan P, Kreahling JM, Morse DL, Grove O, Lloyd MC, Reed D, Raghavan M, Altiok S, Martinez GV, Gillies RJ.

PLoS One. 2013 Dec 16;8(12):e82875. doi: 10.1371/journal.pone.0082875. eCollection 2013.

11.

A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies.

Chamrád I, Rix U, Stukalov A, Gridling M, Parapatics K, Müller AC, Altiok S, Colinge J, Superti-Furga G, Haura EB, Bennett KL.

J Proteome Res. 2013 Sep 6;12(9):4005-17. doi: 10.1021/pr400309p. Epub 2013 Aug 20.

12.

Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.

Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ, Altiok S.

PLoS One. 2013;8(3):e57523. doi: 10.1371/journal.pone.0057523. Epub 2013 Mar 8.

13.

Squamous cell carcinoma with rhabdoid phenotype of skin/soft tissue in a transplant patient: an exceptional case and review of the literature.

Allam-Nandyala P, Bui MM, DeConti R, Purohit C, Altiok S.

Diagn Cytopathol. 2013 Feb;41(2):159-63. doi: 10.1002/dc.21788. Epub 2011 Aug 26. Review.

PMID:
23335454
14.

The histogenic origin of melanoma arising in respiratory epithelium of a teratomatous germ cell tumor of the mediastinum: an enigma unraveled from an unlikely source.

McNab P, Quigley B, Mendoza T, Hakam A, Khalil F, Fishman M, Altiok S.

Int J Clin Exp Pathol. 2012;5(9):982-90. Epub 2012 Oct 20.

15.

Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.

Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G.

Cancer. 2013 Mar 1;119(5):1023-32. doi: 10.1002/cncr.27836. Epub 2012 Oct 12.

16.

EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer.

Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP.

Mol Cancer. 2012 Sep 25;11:73. doi: 10.1186/1476-4598-11-73.

17.

Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.

Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI.

Cancer Res. 2012 Nov 1;72(21):5483-93. doi: 10.1158/0008-5472.CAN-12-2236. Epub 2012 Aug 31.

18.

Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.

Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, Haura EB.

Cancer Res. 2012 May 15;72(10):2501-11. doi: 10.1158/0008-5472.CAN-11-3015. Epub 2012 Mar 29.

19.

Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer.

Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB.

Eur J Cancer Prev. 2012 Sep;21(5):407-12. doi: 10.1097/CEJ.0b013e32834ef194.

20.

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.

Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA.

Br J Cancer. 2012 Jan 3;106(1):77-84. doi: 10.1038/bjc.2011.527. Epub 2011 Dec 1.

21.

MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.

Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S.

Mol Cancer Ther. 2012 Jan;11(1):174-82. doi: 10.1158/1535-7163.MCT-11-0529. Epub 2011 Nov 14.

22.

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.

Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB, Gabrilovich D.

J Clin Invest. 2011 Oct;121(10):4015-29. doi: 10.1172/JCI45862. Epub 2011 Sep 12.

23.

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

Reed D, Altiok S.

Cancer Control. 2011 Jul;18(3):188-95. Review.

PMID:
21666581
24.

The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.

Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer J, Altiok S, Pledger WJ.

Mol Cancer Ther. 2011 Jun;10(6):1018-27. doi: 10.1158/1535-7163.MCT-11-0167. Epub 2011 Apr 13.

25.

Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.

Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E, Altiok S.

PLoS One. 2010 Dec 14;5(12):e14335. doi: 10.1371/journal.pone.0014335.

26.

Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.

Zhang G, Fang B, Liu RZ, Lin H, Kinose F, Bai Y, Oguz U, Remily-Wood ER, Li J, Altiok S, Eschrich S, Koomen J, Haura EB.

J Proteome Res. 2011 Jan 7;10(1):305-19. doi: 10.1021/pr1006203. Epub 2010 Dec 3.

27.

Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers.

Tanvetyanon T, Robinson L, Sommers KE, Haura E, Kim J, Altiok S, Bepler G.

J Thorac Oncol. 2010 Jul;5(7):1018-24. doi: 10.1097/JTO.0b013e3181dd0fb0.

28.

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI.

J Clin Invest. 2010 Apr;120(4):1111-24. doi: 10.1172/JCI40269. Epub 2010 Mar 15.

29.

A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer.

Altiok S, Mezzadra H, Jagannath S, Tsottles N, Rudek MA, Abdallah N, Berman D, Forastiere A, Gibson MK.

Int J Oncol. 2010 Jan;36(1):19-27.

30.

MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.

Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S, Haura EB.

Int J Oncol. 2009 Aug;35(2):337-45.

31.

A plant oxylipin, 12-oxo-phytodienoic acid, inhibits proliferation of human breast cancer cells by targeting cyclin D1.

Altiok N, Mezzadra H, Patel P, Koyuturk M, Altiok S.

Breast Cancer Res Treat. 2008 May;109(2):315-23. Epub 2007 Jul 19.

PMID:
17638069
32.

Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.

Rubio-Viqueira B, Mezzadra H, Nielsen ME, Jimeno A, Zhang X, Iacobuzio-Donahue C, Maitra A, Hidalgo M, Altiok S.

Mol Cancer Ther. 2007 Feb;6(2):515-23.

33.

JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells.

Altiok N, Koyuturk M, Altiok S.

Breast Cancer Res Treat. 2007 Nov;105(3):247-54. Epub 2006 Dec 23.

PMID:
17187235
34.

An in vivo platform for translational drug development in pancreatic cancer.

Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M.

Clin Cancer Res. 2006 Aug 1;12(15):4652-61.

35.

Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.

Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A, Nielsen ME, Maitra A, Altiok S.

Mol Cancer Ther. 2006 Jul;5(7):1895-903.

36.

A 49-year-old woman with a recurring painful soft tissue ankle mass.

Wu JM, Altiok S, Ali SZ.

Arch Pathol Lab Med. 2005 Sep;129(9):1187-8. No abstract available.

PMID:
16119999
37.

Molecular markers in cervical cytology.

Altiok S.

Clin Lab Med. 2003 Sep;23(3):709-28, vii. Review.

PMID:
14560536
38.

Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells.

Altiok S, Batt D, Altiok N, Papautsky A, Downward J, Roberts TM, Avraham H.

J Biol Chem. 1999 Nov 5;274(45):32274-8.

40.
42.

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM.

Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41.

43.

Adipocyte differentiation: a transcriptional regulatory cascade.

Brun RP, Kim JB, Hu E, Altiok S, Spiegelman BM.

Curr Opin Cell Biol. 1996 Dec;8(6):826-32. Review.

PMID:
8939673
45.

Hormonal regulation of transcription factor activity in mammary epithelial cells.

Groner B, Altiok S, Meier V.

Mol Cell Endocrinol. 1994 Apr;100(1-2):109-14. Review.

PMID:
8056143
47.

Supplemental Content

Loading ...
Support Center